Key regions: United Kingdom, Canada, Japan, Europe, China
The demand for dermatological drugs in the United Arab Emirates (UAE) has been steadily increasing over the years.
Customer preferences: The UAE has a high prevalence of skin diseases due to the hot and humid climate, which makes the population more susceptible to skin conditions such as acne, psoriasis, and eczema. This has led to an increased demand for dermatological drugs in the country. Additionally, the population in the UAE is becoming more health-conscious, which has resulted in a growing interest in skincare and dermatological treatments.
Trends in the market: The dermatological drugs market in the UAE is expected to grow in the coming years due to factors such as increasing disposable income, growing awareness about skin health, and an aging population. The market is also being driven by the introduction of new and innovative dermatological drugs, which are more effective and have fewer side effects than traditional treatments. Furthermore, the rise of e-commerce platforms has made it easier for consumers to access dermatological drugs, which has further fueled market growth.
Local special circumstances: The UAE has a unique market for dermatological drugs due to its diverse population. The country has a large expatriate population, which has led to a high demand for dermatological drugs that cater to different skin types. Additionally, the UAE has a high demand for luxury skincare products, which has led to the introduction of high-end dermatological drugs in the market.
Underlying macroeconomic factors: The UAE has a strong economy with a high GDP per capita, which has contributed to the growth of the dermatological drugs market. The country has a well-developed healthcare system, which has made it easier for consumers to access dermatological drugs. Additionally, the UAE has a favorable business environment, which has attracted many international pharmaceutical companies to the country. This has led to the introduction of new and innovative dermatological drugs in the market.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
